-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
Telix presents dosimetry data for prostate cancer drug candidate
-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
Regeneron and Telix form $2.1 billion radiopharmaceutical partnership
-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
FDA accepts Telix brain cancer imaging drug application
-
Telix adds two non-executive directors to board
-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
William Blair Shuffles Analyst Conviction List for April 2026
-
Telix submits European application for brain cancer imaging drug
-
Citi Opens 90-Day Upside Catalyst Watch on Telix Pharmaceuticals Ltd (TLX:AU) (TLX)
-
Telix partners with Varian on cancer imaging and radiation therapy
-
Telix's TLX250-CDx imaging agent included in international renal guidelines
-
Telix doses first patient in bone pain radiopharmaceutical trial
-
Why UBS says Q4 is eventful for SMID oncology stocks
-
CMS grants reimbursement status for Telix's Gozellix prostate imaging agent
-
Citi Opens 90-Day Upside Catalyst Watch on Telix Pharmaceuticals (TLX)
-
Citi Starts Telix Pharmaceuticals Ltd (TLX) at Buy
-
Telix Pharmaceuticals Ltd (TLX) PT Lowered to $20 at H.C. Wainwright
-
JPMorgan Downgrades Telix Pharmaceuticals Ltd (TLX) to Neutral
-
H.C. Wainwright Starts Telix Pharmaceuticals Ltd (TLX) at Buy
-
Telix Pharmaceuticals (TLX) Appoints Paul Schaffer as CTO
-
Telix Pharmaceuticals (TLX) Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
-
Telix Pharmaceuticals (TLX) Announces FDA Approval of Gozellix
-
Telix Pharmaceuticals Limited (TLX) Reports FY results; offers guidance
-
Telix (TLX) announces UK approval of Illuccix
-
Trans-lux Corporation (TLX) Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
-
UBS Starts Telix Pharmaceuticals Ltd (TLX) at Buy

